Physician profile
Brion J Lock
NPI 1295785731
$25,475.68
in general payments reported to CMS, 2019-2025
49 companies · $5,385 in 2025
The $5,385 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $1,412 · 2021: $1,897 · 2022: $2,234 · 2023: $3,767 · 2024: $9,307 · 2025: $5,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,249 · Consulting Fee: $8,870 · Travel and Lodging: $281 · Education: $57.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,249.34 |
| Consulting Fee | $8,870.00 |
| Travel and Lodging | $281.37 |
| Education | $57.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11,432.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,122.95 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,087.44 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,273.50 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Grifols USA, LLC | $1,017.18 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Pfizer INC. | $637.57 | 2019-2025 | |
| Insmed, INC. | $589.85 | 2019-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $506.76 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $506.05 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $448.62 | 2022-2025 | Wakix |
| Axsome Therapeutics, INC. | $426.92 | 2022-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $351.47 | 2020-2023 | |
| Octapharma USA, INC. | $334.23 | 2020-2021 | |
| Mylan Specialty L.P. | $311.66 | 2020-2024 | Yupelri |
| Amgen INC. | $286.51 | 2021-2025 | Tezspire |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brion Lock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.